Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

S2, E1: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

S2, E1: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

FromRaising Biotech


S2, E1: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

FromRaising Biotech

ratings:
Length:
34 minutes
Released:
May 14, 2024
Format:
Podcast episode

Description

In this episode of Raising Biotech, Surani explores the multi-layered start-up story of Israeli lipid nanoparticle biotech Mana.bio. This is a tech meets biotech story, where AI and machine learning is being leveraged to develop novel lipid nanoparticle formulations to get nucleic-acid based therapies (DNA, RNA, CRISPR) to hard to reach organs. The company announced a $19.5 million seed financing in October 2023, and its exciting new chapter was heavily impacted by the October 7 Hamas attacks in Israel. CEO Yogev Debbi gives his tech backstory, decision to move into life-sciences, fundraising journey, what it was like to suddenly navigate a company launch as a wartime CEO and future visions to grow Mana through partnerships and a pipeline. Dr Barry Ticho, a veteran big pharma executive and chief medical officer Stoke Therapeutics, also joins the podcast to give his expert take on Mana's scientific thesis, competitive edge, challenges ahead and future potential to advance the world of gene therapy.Timestamps:00:35 - Partner segment: Mindgram.ai01:05 - Background of Mana.bio and lipid nanoparticle thesis05:30 - CEO Yogev Debbi's tech origins, backstory and Mana.bio formation08:15 - Mana's initial work and "reverse due-diligence" fundraising journey11:15 - Launching the company during an unexpected outbreak of war19:25 - Industry expert perspective (Barry Ticho) on Mana's scientific and business thesis21:55 - Competitive advantage of using AI to optimize the lipid nanoparticle design23:40 - Which organs can these lipid nanoparticles reach in mouse models and non-human primates?27:15 - De-risking events, challenges ahead and safety assurances29:15 - Advantages of tackling new-age biotech with a tech background30:24 - Mana's future business plans: comprehensive partnerships and building a pipelineThis episode is partnered with Mindgram.ai, a research tool powered by AI to better serve the biopharma community. Listeners of the Raising Biotech podcast are able to get an exclusive free trial of Mindgram via this link, using the code: raisingbiotech24For any comments, questions, feedback or suggestions you can connect directly with Surani Fernando on LinkedIn or email: raisingbiotech@gmail.comMusic composed by: Yrii Semchyshyn (Coma Media) Hosted on Acast. See acast.com/privacy for more information.
Released:
May 14, 2024
Format:
Podcast episode

Titles in the series (10)

A narrative podcast series hosted by journalist Surani Fernando that explores biotechs raising impressive funds to develop ambitious medical breakthroughs. Surani speaks with CEOs and founders to get origin stories, missions and future visions for the company, and she also speaks with top experts that help contextualize the biotech's offering and potential to make a healthcare impact. Hosted on Acast. See acast.com/privacy for more information.